Cholesterol Lowering Drug Safe and Effective in Children

Published Online: Wednesday, January 1, 2003
The cholesterol-lowering drug sim-vastatin significantly reduced cholesterol levels in children with inherited high cholesterol, according to a randomized study published in Circulation (October 1, 2002). A total of 173 children (aged 9 to 18 years) with inherited high cholesterol were randomized to up to 40 mg of simvastatin or placebo. After 48 weeks, the children who received simvastatin showed a 41% reduction in low-density lipoprotein, a 31% reduction in total cholesterol, a 34% reduction in apolipoprotein B, a 21% reduction in very low-density lipoprotein, and a 9% reduction in triglycerides. The drug did not affect the growth or maturation of the children.

Latest Articles
Mylan has announced the US launch of clozapine orally disintegrating tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical’s FazaClo.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about some safeguards pharmacists can implement.
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Latest Issues